logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11648269 B1

PDFFull Text
Date of Patent:
May. 16, 2023

Filed:

Aug. 09, 2018

T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof

Applicant:

National University of Singapore, Singapore, SG;

Inventors:

Dario Campana, Singapore, SG;

Takahiro Kamiya, Tokyo, JP;

Assignee:

NATIONAL UNIVERSITY OF SINGAPORE, Singapore, SG;

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Amy E Juedes

Assistant Examiner:

Peter Johansen

Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); A61P 37/06 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/001 (2013.01); A61K 39/0008 (2013.01); A61K 39/001111 (2018.08); A61K 39/001112 (2018.08); A61P 35/02 (2018.01); A61P 37/06 (2018.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C12N 5/0636 (2013.01); C12N 15/62 (2013.01); A61K 2035/122 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/04 (2013.01); C07K 2319/32 (2013.01); C07K 2319/33 (2013.01);
Abstract

The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCRαβ-deficient T cells and CD3/TCRαβ-deficient chimeric antigen receptor T cells that express such PEBLs.

Find Patent Forward Citations

Campana, Dario. (2023). T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof (U.S. Patent No. 11648269). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11648269

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…